Aptima® HPV 16 18/45
Genotype Assay

The next-generation genotype test

HPV types 16, 18 and 45 are associated with up to 94% of HPV-related cervical adenocarcinomas. The Aptima HPV® 16 18/45 genotype assay targets these genotypes, identifying more at-risk women with minimal increase in colposcopy rates.1

HPV Genotypes in Invasive Cervical Cancer2,3

  • Is uncommon and only prevalent in 0.4% of women with normal cytology.2
  • Is the third most common HPV type in invasive cervical cancer.2,3
  • Adenocarcinoma is associated with types 16, 18 and 45.2

Cervical Adenocarcinoma is growing concern

Comparison of incidence in cervical cancer subtypes from 1973 to 2015 show that there has been an encouraging 66% decrease in the average incidence of squamous cell carcinoma. In contrast, adenocarcinoma shows a 35% increase in incidence.4

Histological Subtypes of Cervical Cancer5


Squamous Cell Carcinoma (SCC)


Adenocarcinoma (ADC)

Cytology-negative and HPV-positive co-test results occur in 3.7% of women 30 and older6

Genotyping is recommended for women between the ages of 30-65 with negative Pap but positive HPV test results.7,8 When used in combination with cytology results, our Aptima® HPV Assay and HPV 16 18/45 genotype assay help assess risk and guide patient treatment.
Triage Guidelines for Abnormal HPV Results9

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?

1. Wang N, et al. Histologic follow-up of atypical endocervical cells. Liquidbased, thin-layer preparation vs. conventional papsmear. Acta Cytol. 2002;46:453-457 2. De Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056. 3. Hopenhayn C, et al. Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction. J of Low Genit Tract Dis. 2014;18(3):182-9. 4. Adegoke O, et al. Cervical Cancer Trends in the United States: A 35-Year Population-Based Analysis. J Women Health. 2012;21(10):1031-1037. 5. Islami et al. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med 2019; 123: 316-323. 6. ACOG. Cervical Cancer Screening and Prevention. ACOG Practice Bulletin No. 157. Obstet Gynecol. 2016;127(1):e1-e20. doi:10.1097/AOG.0000000000001263. 7. American Society for Colposcopy and Cervical Pathology. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2013;17(5):S1-S27. 8. ACOG. Management of abnormal cervical cancer screening test results and cervical cancer precursors. ACOG Practice Bulletin No. 140. Obstet Gynecol. 2013;122(6):1338-67. 438960.31355.9e 9. ASCCP. Algorithms: Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests d Cancer Precursors. Published 2013. Accessed September 2, 2020.